https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-11-23 / Melanoma Manag 2017 Dec;4(4):203-215
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-11-23 / Melanoma Manag 2017 Dec;4(4):203-2152017-11-23 00:00:002017-11-23 00:00:00An update on the relevance of vaccine research for the treatment of metastatic melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-11-23 / Int J Hyperthermia 2018 11;34(7):969-979
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-11-23 / Int J Hyperthermia 2018 11;34(7):969-9792017-11-23 00:00:002019-03-27 11:17:45The clinical benefit of hyperthermia in pancreatic cancer: a systematic review
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
IOZK
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
IOZK2017-11-16 16:30:162019-02-10 11:36:36IOZK Vortrag von Stefaan Van Gool: IOZK Immuntherapie bei DIPG Ponsgliom, Konferenz der Society for Neuro-Oncology, San Francisco
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-11-03 / BMJ Open 2017 Nov;7(11):e017387
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-11-03 / BMJ Open 2017 Nov;7(11):e0173872017-11-03 00:00:002017-11-03 00:00:00Clinical and economic evaluation of modulated electrohyperthermia concurrent to dose-dense temozolomide 21/28 days regimen in the treatment of recurrent glioblastoma: a retrospective analysis of a two-centre German cohort trial with systematic comparison and effect-to-treatment analysis
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-11-01 / Cancer Immunol. Immunother. 2018 02;67(2):285-298
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-11-01 / Cancer Immunol. Immunother. 2018 02;67(2):285-2982017-11-01 00:00:002019-02-15 08:49:51A phase I vaccination study with dendritic cells loaded with NY-ESO-1 and α-galactosylceramide: induction of polyfunctional T cells in high-risk melanoma patients
